HeartMate III image courtesy of Thoratec
January 27, 2015 — NewYork-Presbyterian Hospital/Columbia University Medical Center is one of a select group of medical centers participating in a clinical trial of a new device for advanced heart failure patients, the Thoratec HeartMate III Left Ventricular Assist System (LVAS). The device is designed to supplement the heart’s pumping function in patients with left-sided heart failure.
Some 5 million people in the United States are afflicted with congestive heart failure. About 50 percent of people who develop heart failure die within five years of diagnosis.
Doctors at NewYork-Presbyterian/Columbia are evaluating the performance and safety of the HeartMate III in subjects with advanced heart failure. They will help determine the device’s efficacy as a long-term support option for patients who are not candidates for heart transplantation and as a short-term support option for patients awaiting a heart transplant. If successful, the device will improve heart function, blood flow and quality of life for these patients.
Sometimes called a “heart pump” or “LVAD,” the HeartMate III is designed to take over the pumping ability of the weakened heart's left ventricle, which pumps oxygen-rich blood from the lungs throughout the body.
The device is implanted above the diaphragm, immediately next to the heart, and attached to the aorta. A centrifugal blood pump is implanted directly onto the patient's heart, leaving natural circulation in place. In addition, the patient wears an external, wearable controller and battery system to power the pump.
The device offers a number of improvements over its predecessors, including smaller size and a design that mimics the natural pulse rate. The device is fully magnetically levitated, so the parts “float” rather than rub together, which should make it more durable.
For more information: www.nyp.org
April 16, 2024 
